AR032050A1 - Metodo para identificar ligandos de receptores de progesterona especificos para isoformas y ligandos de receptores de progesterona selectivos para tejidos - Google Patents

Metodo para identificar ligandos de receptores de progesterona especificos para isoformas y ligandos de receptores de progesterona selectivos para tejidos

Info

Publication number
AR032050A1
AR032050A1 ARP010106030A ARP010106030A AR032050A1 AR 032050 A1 AR032050 A1 AR 032050A1 AR P010106030 A ARP010106030 A AR P010106030A AR P010106030 A ARP010106030 A AR P010106030A AR 032050 A1 AR032050 A1 AR 032050A1
Authority
AR
Argentina
Prior art keywords
progesterone
isoforms
legends
selective
specific
Prior art date
Application number
ARP010106030A
Other languages
English (en)
Inventor
Fuhrmann Ulrike Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR032050A1 publication Critical patent/AR032050A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para identificar ligandos específicos para isoformas del receptor de progesterona, así como un primer método para identificar ligandos de receptores de progesterona selectivos para tejidos, métodos que comprenden seleccionar ligandos selectivos para la isoforma del receptor de progesterona A o la isoforma del receptor de progesterona B por medio de un ensayo que involucra células transfectadas en forma estable con plásmidos que expresan las isoformas del receptor de progesterona A o B. Además, provee un segundo método para identificar ligandos de receptores de progesterona selectivos para tejidos, que comprende pruebas in vivo en tejidos blanco. También se relaciona con un ligando específico para isoformas del receptor de progesterona y/o selectivo para tejidos identificado mediante los métodos de acuerdo con la presente. Se relaciona además con líneas de células adecuadas para este ensayo de transactivacion, un equipo de ensayo respectivo y usos médicos de los ligandos de receptores de progesterona específicos para isoformas y/o selectivos para tejidos.
ARP010106030A 2000-12-28 2001-12-26 Metodo para identificar ligandos de receptores de progesterona especificos para isoformas y ligandos de receptores de progesterona selectivos para tejidos AR032050A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25831200P 2000-12-28 2000-12-28
US30587501P 2001-07-18 2001-07-18

Publications (1)

Publication Number Publication Date
AR032050A1 true AR032050A1 (es) 2003-10-22

Family

ID=26946565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106030A AR032050A1 (es) 2000-12-28 2001-12-26 Metodo para identificar ligandos de receptores de progesterona especificos para isoformas y ligandos de receptores de progesterona selectivos para tejidos

Country Status (8)

Country Link
EP (1) EP1373888A2 (es)
JP (1) JP2004516841A (es)
AR (1) AR032050A1 (es)
AU (1) AU2002219218A1 (es)
NO (1) NO20032969L (es)
PE (1) PE20020784A1 (es)
UY (1) UY27107A1 (es)
WO (1) WO2002054064A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS89504A (en) * 2002-03-11 2006-10-27 Schering Ag. 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
CN113801889B (zh) * 2021-09-18 2023-04-07 中国农业科学院农业质量标准与检测技术研究所 细胞筛选模型及其构建方法和应用、酵母菌及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene
DE4337416A1 (de) * 1993-10-27 1995-05-04 Schering Ag 10,11beta-C¶2¶-überbrückte Steroide
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE4413185A1 (de) * 1994-04-12 1995-10-19 Schering Ag 11beta,19-überbrückte 13alpha-Alkylsteroide
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene

Also Published As

Publication number Publication date
NO20032969L (no) 2003-08-28
AU2002219218A1 (en) 2002-07-16
WO2002054064A2 (en) 2002-07-11
PE20020784A1 (es) 2002-10-03
UY27107A1 (es) 2002-03-22
JP2004516841A (ja) 2004-06-10
WO2002054064A3 (en) 2003-10-16
NO20032969D0 (no) 2003-06-27
EP1373888A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
MXPA05007067A (es) Sistema de medicion de analitos que previene la reutilizacion de una tira de prueba.
Alaudinova et al. USE OF PHRASAL VERBS IN TESTS ON MEDICAL DISCIPLINES
TW200600782A (en) A method of preventing reuse in an analyte measuring system
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
AR032050A1 (es) Metodo para identificar ligandos de receptores de progesterona especificos para isoformas y ligandos de receptores de progesterona selectivos para tejidos
CR11017A (es) Anticuerpos anti-robo4 y sus usos
CR11058A (es) Polipeptidos de factor vii modificados y usos de los mismos
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
WO2007087261A3 (en) Rapid test apparatus
TW200730129A (en) Method and apparatus for point of care osmolarity testing
SV2011003840A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predicha
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
WO2012120546A3 (en) Method for monitoring anticoagulant therapy
EA200901055A1 (ru) Новый способ производства кексов
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
ATE350662T1 (de) Markerproteine für prostatakrebs
ES2685503T3 (es) Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
ES2509567T3 (es) Identificación de variación genética en tejidos afectados
ES2603616T3 (es) Aparato, método y medio de almacenamiento legible por ordenador para evaluar el estado fisiológico de un paciente
GB2433319A (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
ES2167625T3 (es) Telas no tejidas de grafito como capas funcionales en estuches para pruebas diagnosticas.
BRPI0209172B8 (pt) método de detecção de doenças induzidas por glúten em uma amostra sanguínea de um indivíduo, e kit teste para uso no método
AR117115A1 (es) Métodos para la conservación de reactivo de glóbulos rojos usando monóxido de carbono

Legal Events

Date Code Title Description
FA Abandonment or withdrawal